During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events.
Jean-Bernard Durand, MD
Advertisement
Articles by Jean-Bernard Durand, MD
Advertisement
Latest Updated Articles
Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted TherapiesPublished: March 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Daratumumab Quadruplet Improves Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma
3
Sonrotoclax Combo Shows Safety, Promising Efficacy in R/R Multiple Myeloma
4
Belantamab Mafodotin Triplet Highlights Low Ocular Toxicity in Intermediate-Fit, Frail Newly Diagnosed Myeloma
5
